These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 32789758

  • 1. Identifying optimal magnesium replenishment points based on risk of severe hypomagnesemia in colorectal cancer patients treated with cetuximab or panitumumab.
    Kimura M, Usami E, Teramachi H, Yoshimura T.
    Cancer Chemother Pharmacol; 2020 Sep; 86(3):383-391. PubMed ID: 32789758
    [Abstract] [Full Text] [Related]

  • 2. Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study.
    Schulz C, Heinemann V, Heinrich K, Haas M, Holch JW, Fraccaroli A, Held S, von Einem JC, Modest DP, Fischer von Weikersthal L, Kullmann F, Moehler M, Scheithauer W, Jung A, Stintzing S.
    Anticancer Drugs; 2020 Sep; 31(8):856-865. PubMed ID: 32639280
    [Abstract] [Full Text] [Related]

  • 3. Effects of Type of Antibody to EGFR and Hypomagnesemia on Overall Survival in First-line Treatment of Patients With Unresectable Advanced/Recurrent Colorectal Cancer.
    Kimura M, Usami E, Yoshimura T.
    Anticancer Res; 2020 Dec; 40(12):7135-7140. PubMed ID: 33288613
    [Abstract] [Full Text] [Related]

  • 4. [Analysis of Factors Influencing the Development of Hypomagnesemia in Patients Receiving Cetuximab Therapy for Head and Neck Cancer].
    Inose R, Takahashi K, Nishikawa T, Nagayama K.
    Yakugaku Zasshi; 2015 Dec; 135(12):1403-7. PubMed ID: 26632157
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17.
    Vickers MM, Karapetis CS, Tu D, O'Callaghan CJ, Price TJ, Tebbutt NC, Van Hazel G, Shapiro JD, Pavlakis N, Gibbs P, Blondal J, Lee U, Meharchand JM, Burkes RL, Rubin SH, Simes J, Zalcberg JR, Moore MJ, Zhu L, Jonker DJ.
    Ann Oncol; 2013 Apr; 24(4):953-60. PubMed ID: 23144444
    [Abstract] [Full Text] [Related]

  • 7. Importance of magnesium sulfate supplementation in the prevention of hypomagnesemia and hypocalcemia during chemoradiation in head and neck cancer.
    Grašič Kuhar C, Strojan P, Zadnik V, Zakotnik B.
    J Trace Elem Med Biol; 2018 Dec; 50():327-331. PubMed ID: 30262299
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Hypomagnesemia and Survival in Patients with Ovarian Cancer Who Received Chemotherapy with Carboplatin.
    Liu W, Qdaisat A, Soliman PT, Ramondetta L, Lopez G, Narayanan S, Zhou S, Cohen L, Bruera E, Yeung SJ.
    Oncologist; 2019 Jun; 24(6):e312-e317. PubMed ID: 30940743
    [Abstract] [Full Text] [Related]

  • 10. Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer.
    Ouwerkerk J, Boers-Doets C.
    Eur J Oncol Nurs; 2010 Sep; 14(4):337-49. PubMed ID: 20580896
    [Abstract] [Full Text] [Related]

  • 11. A comparison of panitumumab and cetuximab in the treatment of KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
    Liu T, Jiang S, Teng X, Zhong L, Liu M, Jin Y, Dong M.
    Immunopharmacol Immunotoxicol; 2023 Feb; 45(1):1-9. PubMed ID: 35950851
    [Abstract] [Full Text] [Related]

  • 12. Influence of oral magnesium-containing supplement and antacid administration on hypomagnesemia induced by panitumumab.
    Sato J, Ishikawa H, Tanaka R, Sino M.
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):673-679. PubMed ID: 30661095
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Hypomagnesemia and clinical benefits of anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer: a systematic review and meta-analysis.
    Hsieh MC, Wu CF, Chen CW, Shi CS, Huang WS, Kuan FC.
    Sci Rep; 2018 Feb 01; 8(1):2047. PubMed ID: 29391418
    [Abstract] [Full Text] [Related]

  • 15. Hypomagnesemia During Teriparatide Treatment in Osteoporosis: Incidence and Determinants.
    Bégin MJ, Ste-Marie LG, Coupal L, Ethier J, Räkel A.
    J Bone Miner Res; 2018 Aug 01; 33(8):1444-1449. PubMed ID: 29637622
    [Abstract] [Full Text] [Related]

  • 16. A retrospective analysis on first-line bevacizumab, cetuximab, and panitimumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG).
    Degirmencioglu S, Tanriverdi O, Menekse S, Dogan M, Hacıoglu B, Oktay E, Erdem D, Arpaci E, Uluc BO, Turhal S, Yilmaz M, Pilanci KN, Sakin A, Araz M, Cokmert S, Ozdemir O, Sen E, Nayir E.
    J BUON; 2019 Aug 01; 24(1):136-142. PubMed ID: 30941962
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Isolated hypomagnesemia in a patient treated with capecitabine.
    Rajapakse S, Rodrigo C, Rajapakse AC.
    J Oncol Pharm Pract; 2013 Sep 01; 19(3):254-6. PubMed ID: 22948887
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.